RTI Biologics, a provider of orthopedic and other biologic implants, has reported worldwide revenues of $42.3 million for the third quarter of 2011, up 1 percent compared to the third quarter of 2010.
Quarterly domestic revenues of $37.3 million for the third quarter of 2011 were comparable to the third quarter of 2010. For the third quarter of 2011, the company reported net income of $2.7 million, compared to a. decrease in net income of $134.7 million due to a goodwill impairment charge in the third quarter 2010.
RTI attributed the third quarter to growth in its surgical specialties and bone graft substitute/general orthopedic implants business.
RTI attributed the third quarter to growth in its surgical specialties and bone graft substitute/general orthopedic implants business.
Related Articles on Devices:
Medtronic Introduces MAST MIDLF Procedure for Minimally Invasive Spinal Fusion
Mazor Robotics Announces 15k Implants Using Robotic Spine Surgery Technology
LDR Receives FDA Clearance for Oblique ALIF Cage